A Therapy Treatment Response Trial in Patients With Leptomeningeal Metastases ((LM) Using CNSide

Breast Cancer Clinical Trial

— FORESEE  

Official title:

A Longitudinal Therapy Response Monitoring Study in Subjects With Leptomeningeal Metastases Using CNSide (CSF Tumor Cells) Compared to Standard of Care (CSF Cytology, Clinical Evaluation, and Imaging).

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT05414123
• Other study ID #: BIOC-046
• Status: Terminated
• Start date: September 7, 2022
• Est. completion date: October 13, 2023

Study information

• Verified date: October 2023
• Source: Biocept, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The FORESEE Study is a multi-center, prospective clinical trial enrolling patients with Breast or Non-Small Cell Lung Cancer (NSCLC) who have suspicious or confirmed Leptomeningeal Metastases (LM). Standard of Care methods to diagnose, or assess the treatment response of LM (Clinical Evaluation, MRI and Cytology) have limited sensitivity and specificity. This creates challenges for physicians to manage LM or determine the best course of treatment. CNSide, is a Laboratory Developed Test (LDT ) that is used commercially at the Physician's discretion in Biocept's CLIA certified, CAP accredited laboratory. CNSide can detect and quantify tumor cells in the CSF from patients with Breast Cancer or NSCLC having a suspicious or confirmed LM. The goal of the FORESEE Study is to evaluate the performance of CNSide in monitoring the LM's response to treatment and to assess the impact of CNSide on treatment decisions made by Physicians.

Description:

The FORESEE Study is a multi-center, prospective clinical trial enrolling patients with breast or Non-Small Cell Lung Cancer (NSCLC) who have suspicious or confirmed Leptomeningeal Metastases (LM). LM is a devastating complication of breast cancer and NSCLC and is diagnosed via clinical evaluation, MRI (with and without contrast of the brain and spine), and CSF Cytology. These methods have limited sensitivity and specificity. Furthermore, they lack the ability to quantitatively measure the LM's response to treatment. These hindrances create challenges for physicians to manage LM or to determine the best course of treatment. CNSide, is a Laboratory Developed Test (LDT ) that is analytically validated and run commercially in Biocept's CLIA certified, CAP accredited laboratory at the Physician's discretion. CNSide can detect and quantify tumor cells in the CSF from patients with Breast Cancer or NSCLC having a suspicious or confirmed LM. Data derived from case studies suggest that the detection of tumor cells in the CSF by CNSide can be used by Physicians to monitor the response of the LM tumor to treatment and improve the ability to make treatment decisions in patients with LM. Subjects enrolled onto the trial will be treated per Standard of Care. The diagnostic tests used to either diagnose LM, or monitor the LMs response to treatment will be Standard of Care, in combination with CNSide. The goal of the FORESEE Study is to further evaluate the performance of CNSide for LM in monitoring the LM's response to treatment and to assess the impact of CNSide on treatment decisions made by Physicians.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 40
• Est. completion date: October 13, 2023
• Est. primary completion date: October 13, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

1. Subjects => 18 years of age

2. All genders, races, or ethnic groups,

3. Diagnosed with Breast Cancer or NSCLC who present with clinically suspected LM based on Investigator assessment of radiographic image, cytology, and clinical evaluation.

4. Cytology positive and negative subjects will be included.

5. Subjects willing to provide an Informed Consent.

6. Subjects willing and able to undergo CSF or blood collection via Lumbar Puncture and Ommaya Reservoir as well as veni-puncture and shunt.

7. Both patients with and without parenchymal brain metastases will be eligible as long as leptomeningeal metastases are suspected

8. Subjects who previously had a diagnosis of Leptomeningeal Disease by Investigator assessment of radiographic image and clinical evaluation and cytology.

Exclusion Criteria:

1. Subjects who do not have cancer,

2. Subjects with other types of tumors than breast or lung cancer

3. Subjects diagnosed with a primary brain tumor

4. Subjects who are unable to undergo lumbar puncture, a shunt or veni-puncture.

5. Lack of suspicious LM based in imaging or clinical evaluation.

6. Ordering the Commercial CNSide test while subject is on study

7. Pregnant women and adults lacking capacity to consent for themselves

Related Conditions & MeSH terms

• Breast Cancer
• Leptomeningeal Disease
• Leptomeningeal Metastasis
• Meningeal Carcinomatosis
• Meningeal Neoplasms
• Neoplasm Metastasis
• Non-Small Cell Lung Cancer

Intervention

Device:
• CNSide
The Cerebro-Spinal Fluid (CSF) of subjects enrolled into each cohort will be used for Standard of Care diagnostic assessments used for subjects with either confirmed or suspicious LM (Cytology, protein and glucose) in combination with CNSide analysis.

Locations

Country	Name	City	State
United States	Northwestern University Feinberg School of Medicine	Chicago	Illinois
United States	The University of Texas Southwestern Medical Center	Dallas	Texas
United States	University of Washington	Seattle	Washington
United States	Stanford University	Stanford	California

Sponsors (2)

Lead Sponsor	Collaborator
Biocept, Inc.	ICON plc

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Assess the impact of CNSide on treatment decisions	The proportion of decision points during LM treatment in which the physician indicated that CNSide aided in their decision making.	1 year
Secondary	Evaluate CNSide as a treatment response monitoring device for LM tumors	The correlation of changes in tumor cell number throughout treatment with clinical evaluation, cytology, and radiographic results.	2 years
Secondary	The performance of CNSide of tumor cell detection in the CSF compared to cytology	The comparison of the sensitivity, specificity, PPV and NPV of CNSide to cytology in detection of tumor cells in the CSF (Cytology being the reference standard)	2 years